AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21846371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study 21846636 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 100
Study 21846636 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (TIV)
Number of subjects: 100
Study 21846636 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of LAIV and TIV
Number of subjects: 100
Study 21849262 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 3000000
Study 21849262 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 3000000
Study 21849262 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 3000000
Study 21849262 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 3000000
Study 21849262 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 3000000
Study 21849481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention therapy for life-threatening symptoms (n = 29/38; 76%)
Number of subjects: 135
Study 21849481 — intervention group
Group type: COMPARATOR
Intervention: Observation (no intervention)
Number of subjects: 135
Study 21849481 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk groups based on clinical findings
Number of subjects: 135
Study 21849481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall occurrence of acute myeloid leukemia (AML)
Number of subjects: 135
Study 21849486 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T cells modified to express 19-28z, administered after prior conditioning with cyclophosphamide.
Number of subjects: 10
Study 21849486 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T cells modified to express 19-28z, administered to a patient with relapsed ALL.
Number of subjects: 10
Study 21849486 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T cells modified to express 19-28z, with prior cyclophosphamide administration.
Number of subjects: 10
Study 21849486 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T cells modified to express 19-28z, retrieved 8 days after infusion.
Number of subjects: 10
Study 21850464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and temozolomide (MTDs: 1.3 mg/m² for bortezomib and 200 mg/m² for temozolomide)
Number of subjects: 25
Study 21850464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (with HEIAs)
Number of subjects: 25
Study 21850464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (without HEIAs)
Number of subjects: 25
Study 21850464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and temozolomide (in patients not taking HEIAs)
Number of subjects: 25
Study 21851846 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics (SGA) treatment
Number of subjects: 924
Study 21851846 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants predictive of cardiovascular risk factors
Number of subjects: 924
Study 21852114 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03814735 (80mg QD on Schedule A)
Number of subjects: 57
Study 21852114 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03814735 (50mg QD on Schedule B)
Number of subjects: 57
Study 21852114 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03814735
Number of subjects: 57
Study 21852284 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal Longevity (living to at least 80 years)
Number of subjects: 4000
Study 21852284 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Longevity (living to at least 80 years)
Number of subjects: 4000
Study 21852284 — intervention group
Group type: COMPARATOR
Intervention: Premature Death of Father (death at age < 50 years)
Number of subjects: 4000
Study 21852284 — intervention group
Group type: COMPARATOR
Intervention: Premature Death of Mother (death at age < 50 years)
Number of subjects: 4000
Study 21852295 — intervention group
Group type: EXPERIMENTAL
Intervention: V/Q SPECT scan
Number of subjects: 321
Study 21852295 — intervention group
Group type: EXPERIMENTAL
Intervention: V/Q SPECT scan combined with clinical probability
Number of subjects: 321
Study 21852311 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-Ds with Home Monitoring
Number of subjects: 377
Study 21852311 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictor finding
Number of subjects: 377
Study 21852337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffer dogs applied to exhalation samples from lung cancer patients
Number of subjects: 220
Study 21852337 — intervention group
Group type: COMPARATOR
Intervention: Sniffer dogs applied to exhalation samples from healthy individuals and COPD patients
Number of subjects: 220
Study 21854271 — intervention group
Group type: EXPERIMENTAL
Intervention: Monogamous men (self-reported)
Number of subjects: 360
Study 21854271 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with committed relationships and casual partners
Number of subjects: 360
Study 21854271 — intervention group
Group type: EXPERIMENTAL
Intervention: Monogamous men
Number of subjects: 360
Study 21854593 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended antibiotic treatment with clindamycin and metronidazole plus vaginal gelatine capsules containing different strains of lactobacilli (109 freeze-dried bacteria per capsule)
Number of subjects: 63
Study 21854593 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of partner during follow-up
Number of subjects: 63
Study 21855974 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Sexual Function Index (FSFI)
Number of subjects: 72
Study 21855974 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Endometrial (FACT-En)
Number of subjects: 72
Study 21855974 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiology Studies Depression scale (CES-D)
Number of subjects: 72
Study 21855974 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal Rating Scale (MRS)
Number of subjects: 72
Study 21856678 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation
Number of subjects: 31
Study 21856841 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundwater spiked with Norwalk virus; stored at room temperature in the dark for 61 days.
Number of subjects: 13
Study 21856841 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundwater spiked with Norwalk virus; stored for 1,266 days.
Number of subjects: 13
Study 21856841 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Norwalk virus RNA extracted from virions; stored in groundwater, tap water, and reagent-grade water.
Number of subjects: 13
Study 21856867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 207
Study 21857263 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009-2010 TIV containing B/Brisbane/60/08(Victoria) antigen
Number of subjects: 92
Study 21857263 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010-2011 TIV containing B/Brisbane/60/08(Victoria) antigen
Number of subjects: 92
Study 21857286 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine, lamivudine, efavirenz (once-daily administration)
Number of subjects: 51
Study 21857490 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) 800/100 mg once daily and Raltegravir (RAL) 400 mg twice daily
Number of subjects: 112
Study 21857490 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) plus Raltegravir (RAL)
Number of subjects: 112
Study 21857793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (school-based curriculum to delay sexual initiation)
Number of subjects: 16
Study 21857793 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study 21858552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib followed by Sunitinib (SOR-SUN)
Number of subjects: 33
Study 21858552 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib followed by Sorafenib (SUN-SOR)
Number of subjects: 33
Study 21859168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hangover insensitivity at Time 1
Number of subjects: 134
Study 21859168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hangover severity at Time 1
Number of subjects: 134
Study 21859168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hangover sensitivity at Time 1
Number of subjects: 134
Study 21859692 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg or 2 mg/kg (≤40 kg) subcutaneously every 8 weeks for up to 2 years
Number of subjects: 166
Study 21859696 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant-free influenza A/California/7/2009 (pH1N1) vaccine
Number of subjects: 340
Study 21859696 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 340
Study 21860025 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP70 risk stratification
Number of subjects: 45
Study 21860025 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP15 risk stratification
Number of subjects: 45
Study 21860025 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH based risk stratification
Number of subjects: 45
Study 21860347 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir and Truvada for 52 weeks
Number of subjects: 16
Study 21860633 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 1-month depot administered intramuscularly every 28 days.
Number of subjects: 55
Study 21860975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 18
Study 21861537 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg once-daily
Number of subjects: 0
Study 21861537 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once-daily
Number of subjects: 0
Study 21861537 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 0
Study 21861537 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 21861537 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular weight heparin/warfarin
Number of subjects: 0
Study 21862407 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice a day
Number of subjects: 91
Study 21865328 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body weight-adjusted abdominal fat mass (AFM)
Number of subjects: 629
Study 21865328 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat mass (TFM)
Number of subjects: 629
Study 21865328 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-adjusted AFM increase
Number of subjects: 629
Study 21865346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg once-daily dosing
Number of subjects: 288
Study 21865361 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 115
Study 21865361 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue (SAT)
Number of subjects: 115
Study 21865361 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh fat
Number of subjects: 115
Study 21865361 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 115
Study 21865361 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT tertile grouping
Number of subjects: 115
Study 21865561 — intervention group
Group type: EXPERIMENTAL
Intervention: TCN2 67AG genotype
Number of subjects: 2411
Study 21865561 — intervention group
Group type: EXPERIMENTAL
Intervention: TCN2 67GG genotype
Number of subjects: 2411
Study 21865561 — intervention group
Group type: COMPARATOR
Intervention: TCN2 67AA genotype
Number of subjects: 2411
Study 21865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of TCN2 67AG in strata of 776CC
Number of subjects: 2411
Study 21865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of TCN2 67GG in strata of 776CC
Number of subjects: 2411
Study 21865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of TCN2 67AG in strata of 776CG
Number of subjects: 2411
Study 21865561 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of TCN2 67GG in strata of 776CG
Number of subjects: 2411
Study 21867401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA) 1.3 g administered three-times daily for up to 5 days per menstrual cycle (maximum of 15 doses)
Number of subjects: 723
Study 21867401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA)
Number of subjects: 723
Study 21867539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, interprofessional mental health promotion intervention (6-month program with regular home visits and monthly case conferences)
Number of subjects: 250
Study 21867539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, interprofessional mental health promotion intervention
Number of subjects: 250
Study 21867843 — intervention group
Group type: EXPERIMENTAL
Intervention: Midregion proadrenomedullin (MR-proADM)
Number of subjects: 1641
Study 21868014 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy with genetic variant analysis for COQ2 (rs4693570)
Number of subjects: 793
Study 21868014 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy with genetic variant analysis for ATP2B1 (rs17381194)
Number of subjects: 793
Study 21868014 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy with genetic variant analysis for DMPK (rs672348)
Number of subjects: 793
Study 21868463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal stent placement
Number of subjects: 103
Study 21868463 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative tracheobronchoplasty (TBP)
Number of subjects: 103
Study 21868463 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured FEV(1) and exercise capacity (6-min walk test)
Number of subjects: 103
Study 21868572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose of donor T cells (2 × 10(8)/kg)
Number of subjects: 27
Study 21868572 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 27
Study 21868572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without disease at HSCT
Number of subjects: 27
Study 21868778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glucose suspend (LGS) feature of the Paradigm Veo insulin pump
Number of subjects: 31
Study 21869687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d for 1 year
Number of subjects: 599
Study 21871057 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut oil (0.5 mg/mL)
Number of subjects: 0
Study 21871057 — intervention group
Group type: EXPERIMENTAL
Intervention: Human sera (10%, v:v) from walnut feeding study
Number of subjects: 0
Study 21871057 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA)
Number of subjects: 0
Study 21871057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (walnut intake)
Number of subjects: 0
Study 21873548 — intervention group
Group type: COMPARATOR
Intervention: SNP rs11554137 positive patients in adult AML
Number of subjects: 527
Study 21873548 — intervention group
Group type: COMPARATOR
Intervention: SNP rs11554137 positive patients in adult AML achieving complete remission
Number of subjects: 527
Study 21873548 — intervention group
Group type: COMPARATOR
Intervention: SNP rs11554137 positive patients with normal cytogenetics
Number of subjects: 527
Study 21873548 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs11554137 positivity in adult AML
Number of subjects: 527
Study 21874061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study 21874317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic cyclophosphamide (CTX) 65 mg/m² daily on days 1-14 plus capecitabine 1,000 mg/m² twice daily on days 1-14, repeated every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Number of subjects: 68
Study 21875676 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hip osteoarthritis
Number of subjects: 1010
Study 21875676 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic knee osteoarthritis
Number of subjects: 1010
Study 21875676 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized prevalence of hip OA
Number of subjects: 1010
Study 21875676 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized prevalence of knee OA
Number of subjects: 1010
Study 21876119 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy at maximum tolerated dose (MTD)
Number of subjects: 174
Study 21876119 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 174
Study 21877169 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab, 600 mg every 2 weeks
Number of subjects: 1
Study 21877169 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (initial treatment)
Number of subjects: 1
Study 21877508 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate spray 0.05% in the morning and calcitriol ointment 3 microg/g in the evening for up to 4 weeks
Number of subjects: 0
Study 21877895 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS/MS assay for detecting keratan sulfate-derived disaccharides in urine and plasma
Number of subjects: 168
Study 21880642 — intervention group
Group type: EXPERIMENTAL
Intervention: High pentraxin 3 levels on day 0
Number of subjects: 100
Study 21880803 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention (nutrition education, exercise training, behavior therapy)
Number of subjects: 59
Study 21883440 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate psychological stress (Trier Social Stress Test) in the postprandial state (75 min after a standard meal)
Number of subjects: 30
Study 21883440 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate psychological stress (Trier Social Stress Test) in the fasting state
Number of subjects: 30
Study 21883440 — intervention group
Group type: COMPARATOR
Intervention: Control day (no stress)
Number of subjects: 30
Study 21884592 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric tumor necrosis factor (TNF)-induced knee arthritis in TNF-Tg mice
Number of subjects: 0
Study 21884947 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Number of subjects: 373
Study 21884947 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 373
Study 21884947 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant-free survival
Number of subjects: 373
Study 21884947 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival free of heart failure hospitalization
Number of subjects: 373
Study 21884947 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF
Number of subjects: 373
Study 21884947 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic diameter at presentation
Number of subjects: 373
Study 21884952 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain-encoded magnetic resonance imaging (SENC) during high-dose dobutamine stress cardiac magnetic resonance imaging (DS-MRI)
Number of subjects: 320
Study 21884952 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting and inducible wall motion abnormalities (WMA)
Number of subjects: 320
Study 21884952 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual SENC or quantitative strain rate reserve
Number of subjects: 320
Study 21884952 — intervention group
Group type: EXPERIMENTAL
Intervention: SENC in a subset of patients who underwent coronary angiography (n = 175)
Number of subjects: 320
Study 21885599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured red blood cells (cRBCs)
Number of subjects: 1
Study 21885601 — intervention group
Group type: EXPERIMENTAL
Intervention: Management approaches for ALPS and its associated cytopenias
Number of subjects: 500
Study 21885723 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at high altitude
Number of subjects: 15
Study 21885723 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced pulmonary hypertension
Number of subjects: 15
Study 21885723 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation
Number of subjects: 15
Study 21885725 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of asthma (SOA) score
Number of subjects: 2878
Study 21885725 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control test (ACT)
Number of subjects: 2878
Study 21885725 — intervention group
Group type: EXPERIMENTAL
Intervention: Work productivity and impairment index-asthma (WPAI-A)
Number of subjects: 2878
Study 21885725 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV(1) % predicted
Number of subjects: 2878
Study 21885890 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for physical activity assessment
Number of subjects: 491
Study 21885891 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 7500 steps/day
Number of subjects: 985
Study 21885891 — intervention group
Group type: COMPARATOR
Intervention: < 7500 steps/day
Number of subjects: 985
Study 21885891 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater steps/day (combined for men and women)
Number of subjects: 985
Study 21887501 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m2
Number of subjects: 15
Study 21887501 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 0.7-2.0 mg/m2
Number of subjects: 15
Study 21888637 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m² IV on days 1 and 8) and capecitabine (900 mg/m² orally twice a day on days 1-14)
Number of subjects: 32
Study 21888637 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel and capecitabine
Number of subjects: 32
Study 21889330 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5mg twice daily)
Number of subjects: 64
Study 21889574 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR treatment
Number of subjects: 155
Study 21890147 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥3 severe pain episodes
Number of subjects: 307
Study 21890147 — intervention group
Group type: COMPARATOR
Intervention: <3 severe pain episodes
Number of subjects: 307
Study 21890206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (IV NAC)
Number of subjects: 62
Study 21890206 — intervention group
Group type: COMPARATOR
Intervention: Oral N-acetylcysteine (oral NAC)
Number of subjects: 62
Study 21890336 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma population
Number of subjects: 74